Lead Generation Strategies


Finding new drugs leads for medical conditions with unmet solutions is one of the biggest hurdles in recent drug discovery as the ‘obvious’ drug candidates have already been found. Plus, there are more molecular targets to develop new drugs against thanks to the rapid pace of medical research. Many of these new molecular targets are more complex, such as protein-protein interactions (PPIs) or protein-nucleic acid complexes and move ‘drug hunters’ into less explored chemical space from which to find or design appropriate lead compounds. Luckily synthetic chemistry and other innovations have expanded the chemical space new drug leads can occupy while still fitting the properties of a ‘good drug’. Join fellow discovery chemists and biologists at the Lead Generation Strategies conference to review the various advances and strategies for finding and creating novel drug leads in today’s expanded chemical and molecular universe.

Preliminary Agenda

Progressing from Target Hits to Drug Leads

Interplay Between Lead Generation and Target Validation in AbbVie Early Chemistry:  A Wild-Type Isocitrate Dehydrogenase 1 Case Study
J. Brad Shotwell, PhD, Senior Principal Scientist, Tool and Lead Generation Chemistry Group Leader, Abbvie

Exploiting Pilot Screen Hits to Pressure-Test HTS Screening Triage Funnels
Michael Finley, PhD, Principal Scientist, Screening, Discovery Sciences, Janssen R&D

A Phenotypic Screen for ALS
Dean G. Brown, PhD, Director, External Chemistry, Hit Discovery, Discovery Sciences, IMED Biotech Unit, Astra Zeneca

Case Study: Phenotypic Screen Deconvolution of Mechanism of Action
Martin Pettersson, PhD, Associate Research Fellow, Internal Medicine & Medicinal Chemistry, Pfizer

Encoded Library Technologies to Identify Small- and Medium-Sized Starting Points for Lead Generation
Jonas V. Schaefer, PhD, Laboratory Head, Encoded Library Technologies, Novartis Institutes for Biomedical Research, Chemical Biology & Therapeutics (CBT), Novartis Pharma AG

Fragment-Based Approaches

Fragment Screening to Assess Target Ligandability
Fredrik Edfeldt, PhD, Structure, Biophysics & Fragment-Based Lead Generation, AstraZeneca R&D Gothenburg, Sweden

Target-Based Screens to Find Covalent Fragments to Aid Drug Lead Generation
Alexander Statsyuk, PhD, Assistant Professor, Department of Pharmacological and Pharmaceutical Sciences, University of Houston

Fragment-Based Covalent Ligand Screening to Target the Ubiquitin System
Katrin Rittinger, PhD, Group Leader/Principal Investigator, Molecular Structure of Cell Signaling, The Francis Crick Institute, UK

Talk Title To be Announced
Gianni Chessari, PhD, Senior Director, Computational Chemistry and Informatics, Astex Pharmaceuticals

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Update History
Event Information updated

Premier Sponsors

Ablexis Alivamab_stacked



OmniAb Ligand_Pharmaceuticals